Cheap Stocks to Buy Now

7 beaten-down stocks worth watching

Quick answer: Cheap stocks can offer upside, but only when the market is mispricing the risk. Belanger Trading is watching beaten-down, recognizable names where investor sentiment may already be washed out, but the business still has a path to recovery. This list is not about penny stocks or low share prices. It is about companies where the market may be too pessimistic — and where investors need to decide whether the stock is a bargain or broken.

Last updated: May 30, 2026 — Belanger Trading updates this page as valuations, earnings, and risk/reward change. Market and company data as of May 29–30, 2026, sourced and dated below.

By Belanger Trading research desk

Cheap stocks are seductive — and that is the problem

Cheap stocks are seductive. A stock that has already fallen 40%, 50%, or 60% feels like it should have less risk. That is not always true. Sometimes the market overreacts. Sometimes the market is right. The job is to separate a bargain from a broken company.

The names below are not the lowest-priced tickers on the screen, and they are not lottery tickets. They are companies you already recognize — Nike, PayPal, Target, Disney, Pfizer, AT&T — that have been beaten down hard enough to look cheap. Every one of them got cheap for a reason. The whole question is whether that reason is temporary or permanent.

Here is the line to keep at the front of your mind for this entire page: cheap does not mean good. Cheap means the market is pricing in disappointment. The question is whether the disappointment is temporary or permanent.

Every great trade or investment starts with deep research. Treat the names below as the start of yours, not the end of it.

Cheap vs. broken: the only distinction that matters

A beaten-down stock falls into one of two buckets, and they look identical on a screener.

Bucket 1 — the market may be too pessimistic. The price is low because investors are extrapolating a bad stretch into forever. The business still has real revenue, real cash flow, a real franchise, and a path back. The discount is about sentiment, not the underlying engine. When the market is wrong about how permanent the problem is, that is where opportunity lives.

Bucket 2 — the business is actually deteriorating. The price is low because the company is losing ground for real: a melting franchise, a balance sheet that can’t fund the turnaround, dilution that shrinks your slice every quarter, or a structural decline the market has correctly identified. Here, “cheap” is a trap, and buying it destroys capital slowly.

The difference is never in the price. It is in the business behind the price. A stock is only interesting to us when the risk/reward is mispriced — when what you make if you are right is large relative to what you lose if you are wrong, and the reason for the discount is something the market is getting wrong rather than getting right.

That is the spine of this page. Every name below gets sorted against it.

How we chose these stocks

This is a research watchlist, not a list of buy orders. A name earns a spot here when it clears a set of questions — and notably, we did not include obscure names just because they are interesting to us. These are companies real investors are already searching, already own, or already wondering about:

• Is it recognizable? You should already know what the company does. That is the point of this list.
• Has it actually reset? A real valuation reset or a beaten-down chart — not just a stock that drifted sideways.
• Is there a real business underneath? Revenue, cash flow, assets, or a franchise that survives a rough patch.
• Is there a possible catalyst? Something specific that could change how the market sees it.
• Is there a clear reason for the skepticism? We want to name why it is cheap. A cheap stock with no visible reason usually means we have not looked hard enough.
• Is the risk understandable? Stated plainly, in one sentence, for every name.
• Is there a path to a re-rating? A reason the discount could close, not just a hope that it will.

Where the options market adds a useful clue, we will say so. The option flow never replaces the work on the business.

The watchlist at a glance

Seven recognizable beaten-down names. Each could become interesting if the market is too pessimistic, and each carries a real, nameable reason it got cheap. Stances are editorial positioning — how we would frame the setup today — not personalized advice.

“Watch” means the thesis is intact and we are tracking it. It does not mean buy all seven today. Separate the company from the setup: a great company can still be a poor entry, and a cheap price is not the same as a good one.

1. Nike (NKE) — an iconic brand that no longer gets the benefit of the doubt

What the company does. Nike is the largest athletic-footwear and apparel brand in the world, selling through wholesale partners and its own direct-to-consumer channels.

Why it looks cheap. Nike trades around $46 per share, down sharply from a 52-week stretch that reached the $80 range, with a market cap near $68 billion and a dividend yield around 3.5% (as of May 29, 2026). The stock has been cut hard from its highs, which is why it shows up on “beaten-down” screens. What it is not is statistically cheap on earnings: it still trades at roughly 28 times forward earnings and 30 times trailing (as of May 29, 2026). The cheapness here is “great brand, deeply out of favor,” not “single-digit multiple.”

Why the market is skeptical. Nike is in the middle of a turnaround that is taking longer than hoped. In its fiscal Q3 2026 (quarter ended February 2026), revenue was about $11.3 billion and net income fell 35% to $520 million, while Greater China revenue fell 7% — and management guided to a roughly 20% China decline in the following quarter, the seventh straight quarter of declines in that market. Gross margin slipped to about 40.2%, pressured by higher tariffs. The market’s worry is real: a slower product cycle, tougher competition from newer brands, and a China business that keeps shrinking.

What could change the story. CEO Elliott Hill’s “Win Now” turnaround is showing early signs in the most important market: North America revenue rose 3% and footwear rose 6% in fiscal Q3 2026. Hill has acknowledged the recovery is taking “longer” than he expected but said the “direction is clear.” If North America keeps re-accelerating and China stops getting worse, the market’s view of Nike as a stalled brand could shift.

The main risk. The turnaround stalls — China keeps sliding, the product cycle stays cold, and the brand keeps losing relevance to competitors. A premium multiple on a brand that is no longer growing is the most dangerous combination on this list.

The Belanger Take. Nike is the clearest “brand still matters, but no longer gets the benefit of the doubt” name we are watching. For years the market would pay almost any price for the swoosh. Now it is demanding proof, and it is right to. This is a turnaround watchlist name, not a blind buy — the brand is real, but you are paying a full multiple for a recovery that has not finished, and the China decline is not finished either. We would watch the North America trajectory and the China trend together; those two lines decide whether the swoosh is reaccelerating or just resting.

2. PayPal (PYPL) — cheap because the market doubts the franchise

What the company does. PayPal runs one of the largest digital-payments networks in the world, including its branded checkout button, the PayPal app, and Venmo.

Why it looks cheap. PayPal trades around $45 per share at roughly eight times earnings, with a similar forward multiple (as of May 29, 2026). For a profitable, cash-generating business with hundreds of billions in annual payment volume, that is a strikingly low multiple — the kind the market usually reserves for companies it thinks are in decline.

Why the market is skeptical. The fear is that PayPal’s core checkout business is losing ground. Apple Pay, big retailers’ own wallets, and other “buy now” buttons are all competing for the same checkout. PayPal’s own board has acknowledged that results, particularly in branded checkout, “fell short of expectations”, and the company is reorganizing into a simpler three-business structure to refocus. In Q1 2026, branded checkout volume grew just 2% on a currency-neutral basis — slow for the business that defines the company.

What could change the story. The numbers are not those of a broken company. Q1 2026 revenue rose about 7% year over year to $8.35 billion, earnings came in at $1.34 per share, total payment volume reached $464 billion, and Venmo volume grew 14% — its sixth straight quarter of double-digit growth. The company also bought back about 34 million shares for $1.5 billion in the quarter, shrinking the share count. If branded checkout growth re-accelerates even modestly, an eight-times multiple looks too pessimistic.

The main risk. Competition keeps chipping away at branded checkout faster than Venmo and newer products can offset it. A low multiple on a slowly shrinking franchise is not a bargain — it is a value trap. The whole question is whether the core stabilizes.

The Belanger Take. PayPal is the classic “is it cheap or is it broken?” debate in a single ticker. The bull case is that the market has priced a profitable payments leader like it is dying, when the cash flow and Venmo say otherwise. The bear case is that checkout is a melting ice cube and eight times earnings is exactly right. It works only if PayPal defends its margins, grows users, and stays relevant in a crowded payments world — so we would watch the branded-checkout growth line above everything else. That one number decides which story is true.

3. United Parcel Service (UPS) — a beaten-down bellwether in the middle of surgery

What the company does. UPS is one of the largest package-delivery and logistics companies in the world, moving millions of parcels a day across its U.S. domestic and international networks.

Why it looks cheap. UPS trades around $107 per share at roughly 14 times forward earnings, 17 times trailing, with a dividend yield near 6.1% (as of May 29, 2026). A near-6% yield on a recognizable blue chip is the market telling you it does not trust the current profit level — the classic beaten-down-quality setup, where the stock is cheap because earnings have fallen and nobody is sure where they settle.

Why the market is skeptical. UPS is mid-transformation, and the numbers show the strain. In Q1 2026, consolidated revenue was about $21.2 billion and adjusted operating margin was 6.2% — well below the 9–12% margins UPS posted at its peak — while U.S. domestic operating profit fell to $515 million from $979 million a year earlier. The company has said recovering to peak margins could take until 2028 or beyond. UPS is deliberately shedding low-margin Amazon volume (its “glidedown”) and reconfiguring its network — necessary surgery, but it depresses revenue and profit while it happens. On top of that, package volumes are tied to the economy, labor costs, and trade.

What could change the story. Management is sticking with full-year 2026 guidance of roughly $89.7 billion in revenue and an adjusted operating margin near 9.6%, and has said the heaviest cost pressure from the Amazon glidedown and network changes is largely behind it. Revenue per piece grew 6.5% in the U.S. in Q1 2026, a sign the mix shift toward more profitable packages is working. If volumes stabilize as the restructuring finishes, the margin can recover and the dividend looks better covered.

The main risk. This is the central question on UPS: is the weakness cyclical (volumes and margins recover with the economy and the restructuring) or is it a permanent margin reset (e-commerce economics and competition mean UPS never gets back to peak profitability)? A weak economy on top of the transition would make the dividend look stretched and the “cheap” multiple justified.

The Belanger Take. UPS is a classic beaten-down quality name — a real franchise, a real dividend, real cash flow, trading at a price that assumes the good years are over. We do not think it is broken; we think it is being operated on, and surgery is ugly while it happens. The honest debate is cyclical-weakness-versus-permanent-reset, and you will not resolve it from one quarter. Watch domestic volume trends and the operating margin as the Amazon glidedown finishes — if those turn, the yield was the market paying you to wait; if they don’t, the discount was earned.

4. Target (TGT) — a beaten-down retailer showing early signs of a turn

What the company does. Target is a large U.S. general-merchandise retailer, selling everything from groceries to apparel to home goods across roughly 2,000 stores and a growing digital business.

Why it looks cheap. Target trades around $127 per share at roughly 15 times forward earnings, 17 times trailing, with a dividend yield near 3.6% (as of May 29, 2026). The stock fell from roughly $177 in 2024 to a 52-week low near $83 in late 2025 before recovering — so even at $127 it is well off its highs, on a single-digit-growth retailer the market soured on.

Why the market is skeptical. The skepticism is earned by a genuinely weak 2025. For full-year 2025, net sales and operating income fell about 1.7% and 8.1% respectively, and Q4 comparable sales declined 2.5% — soft consumer confidence hit Target’s cost-conscious core shopper, and execution stumbled. This is a “show me” retailer: the market wants proof that traffic, margins, and merchandising can recover before it pays up.

What could change the story. The early evidence of a turn is real. In Q1 2026, comparable sales rose 5.6% (versus a 3.8% decline a year earlier), driven by a 4.4% traffic increase, with gross margin improving about 80 basis points. New CEO Michael Fiddelke is running a reset, and the company announced more than $2 billion of incremental 2026 investment in stores and the guest experience. If traffic growth holds and margins keep recovering, the discount to its own history is hard to justify.

The main risk. The turn stalls. One strong quarter is not a trend — Target has had head-fakes before, the consumer can stay cautious, and the heavy reinvestment pressures margins in the near term. Execution is the whole game here, and execution is exactly what wobbled in 2025.

The Belanger Take. Target is not broken just because the stock got cut in half from its peak — it is a profitable, cash-generating retailer that lost the thread and is trying to find it again. But “not broken” is not the same as “fixed.” The Q1 2026 comp and traffic numbers are the most encouraging data point in two years, and they are exactly the metrics that matter; the job now is proving they repeat. We would watch traffic and margins quarter over quarter — a beaten-down retailer that gets its core shopper back is a different stock, but it has to earn it more than once.

5. Alibaba (BABA) — statistically cheap, with China stapled to the thesis

What the company does. Alibaba is China’s largest e-commerce and cloud-computing group, spanning domestic and international online marketplaces, the Cloud Intelligence Group, logistics, and a fast-growing AI business.

Why it looks cheap. Alibaba’s U.S.-listed ADS trades around $124 with a market cap near $284 billion and roughly 18–19 times earnings (as of May 29, 2026). For a company growing its cloud and AI business at the rate it is, that multiple looks low on a sum-of-the-parts basis — and on cash and asset value, many analysts argue the stock has long traded at a steep “China discount.” It is the deep-value name on this list: statistically cheap, but cheap in a way that comes with a country attached.

Why the market is skeptical. The discount is about risk that has nothing to do with the multiple. China regulatory policy, U.S.–China geopolitics, the structure of the VIE that U.S. holders actually own, and questions about how shareholder-friendly Chinese tech really is — all of it keeps a lid on the valuation. A stock can stay statistically cheap for years when investors do not trust the rules of the game.

What could change the story. The business engine is running. In fiscal 2026 (year ended March 31, 2026), total revenue was about $148.4 billion, up 3% as reported (11% on a like-for-like basis), and the Cloud Intelligence Group grew 34% for the full year, with AI-related products posting triple-digit growth for an eleventh straight quarter. Alibaba also returns capital: it declared an annual dividend of $1.05 per ADS (about $2.5 billion total) for fiscal 2026, and its board buyback program — under which it repurchased $11.9 billion of stock in fiscal 2025 with roughly $20.1 billion of authorization remaining as of March 31, 2025, effective through March 2027 — is a lever it can keep pulling. A sustained shift in China sentiment, continued AI-cloud monetization, and steady capital returns are what would close the gap.

The main risk. China. Regulatory, geopolitical, and trust risk can override any amount of statistical cheapness, and U.S. holders own an offshore structure, not the operating company directly. This is the name where “cheap” can persist far longer than a Western value investor expects.

The Belanger Take. Alibaba can look absurdly cheap for years — that is the trap and the opportunity in the same sentence. The cloud and AI growth is real and the capital returns are real, but valuation alone has never been the catalyst here; what re-rates this stock is a change in how the market prices China risk, not another good earnings line. We treat it as a deep-value, high-variance idea where the discount is the point and the country is the risk. Size it for the fact that the thing that would unlock the value is mostly outside the company’s control.

6. Pfizer (PFE) — beaten-down quality with an income kicker

What the company does. Pfizer is one of the largest pharmaceutical companies in the world, with a portfolio spanning vaccines, oncology, cardiology, and now obesity treatments.

Why it looks cheap. Pfizer trades around $26 per share, near multi-year lows, at roughly nine times forward earnings with a dividend yield near 6.6% (as of May 29, 2026). That is a deep discount to the broad market and to most large drugmakers. The stock has spent the last couple of years grinding lower as pandemic-era COVID revenue faded.

Why the market is skeptical. This is the textbook “cheap for a reason” worry, and it is a real one. Pfizer faces a patent cliff: Eliquis and Xeljanz lose U.S. exclusivity in 2026, with Ibrance and Xtandi following in 2027. When a blockbuster drug loses patent protection, cheaper generics arrive and revenue can drop fast. On top of that, the dividend — the main reason many people own it — sits on a stretched earnings-based payout ratio near 99% (as of January 2026), which leaves little room for error.

What could change the story. Pfizer is trying to replace lost revenue with new sources of growth: oncology, and a push into the obesity-drug market through its Metsera acquisition, with Phase 3 data on an obesity candidate expected in 2026. Strong data there would give the market a reason to look past the patent cliff. The company has reaffirmed full-year 2026 guidance of $59.5–$62.5 billion in revenue and adjusted EPS of $2.80–$3.00, and has paid a dividend every quarter for decades — returning $2.4 billion to shareholders in Q1 2026 alone.

The main risk. The pipeline does not refill the hole fast enough, and the high payout ratio forces a hard choice on the dividend. A cut would hit the stock and the thesis at the same time.

The Belanger Take. Pfizer is the cleanest example on this list of a stock that is genuinely cheap and carries a genuine risk — the two are not in conflict, they are the whole point. The market is paying you a near-6.6% yield to wait out a patent cliff it has already decided will be bad. The setup only improves if the pipeline and the obesity bets offset the post-COVID hangover before the dividend math gets ugly. That is a watch-and-verify story, not a sure thing — but it is a real business at a real discount, which is more than most “cheap” stocks can say.

7. Bristol Myers Squibb (BMY) — pharma value with a patent cliff on the horizon

What the company does. Bristol Myers Squibb is a large pharmaceutical company whose portfolio spans oncology, cardiovascular, immunology, and neuroscience, including drugs like Eliquis (co-marketed with Pfizer), Opdivo, and a growing list of newer launches.

Why it looks cheap. BMY trades around $57 per share at roughly nine times forward earnings, with a dividend yield near 4.4% (as of May 29, 2026) — a meaningful discount to most large-cap pharma peers. It is the value-and-income name in the group, with 17 consecutive years of dividend increases. On a backward-looking basis it screens cheap; the question is what the earnings look like a few years out.

Why the market is skeptical. Like Pfizer, BMY faces a patent cliff. Eliquis and Opdivo, two of its top sellers, lose U.S. exclusivity around 2028, and older drugs like Revlimid are already eroding to generics. The company guided to 2026 revenue of roughly $46–$47.5 billion, down from about $48.2 billion in 2025 — a business the market sees shrinking before it grows again. A low multiple on a company heading into a patent cliff is the market pricing in the decline.

What could change the story. BMY’s whole bull case is that its newer “growth portfolio” replaces what is going off patent. Management has pointed to a heavy slate of pivotal data readouts in 2026 across neuroscience (Cobenfy), cardiovascular (Milvexian), immunology, and oncology, with more registrational data expected through 2028. If enough of those land, the next product cycle can offset the losses and the discount looks too steep. If they don’t, the cliff wins.

The main risk. Patent losses outrun the new launches. Pipeline drugs fail, get delayed, or underwhelm commercially, and the revenue hole from Eliquis, Opdivo, and Revlimid opens faster than the replacements fill it. A cheap multiple does not protect you from a shrinking earnings base.

The Belanger Take. BMY appeals to the value-and-income investor for good reasons — a low multiple, a well-supported dividend, and a deep pipeline. But the market is not being irrational; it is demanding evidence that the next product cycle can actually replace what is being lost, and that evidence arrives drug by drug over the next few years. This is a “watch the readouts” name, not a set-and-forget one. We would track the 2026 pivotal data and the trajectory of the new launches — those decide whether nine times earnings is a bargain or a fair price for a company about to shrink.

Other cheap stocks we’re watching

Three more recognizable names are on the radar but did not make the main seven — each for a specific reason.

Kraft Heinz (KHC) is the defensive, packaged-food value name. It trades around $24 with a dividend yield near 6.5% and a forward multiple around 12 (as of May 29, 2026), and it carries a high yield because growth has been slow and brands have lost ground to cheaper and healthier alternatives. The company had announced plans to split into two companies, then paused that separation in early 2026 as a new CEO said the problems were “fixable”. It is cheap and pays you well to wait, but the catalyst is slow and the turnaround is unproven — a sleepier story than the main seven.

Disney (DIS) is the recognizable turnaround with a deep bench of irreplaceable brands, parks, and franchises. It trades around $102 at roughly 14 times forward earnings (as of May 29, 2026), well off its old highs. The bull case is real: streaming has turned profitable and the parks business posted record operating income, so this is less “broken” than “complex, multi-engine company the market is still re-rating.” We keep it on the bench mainly because the execution story has many moving parts; it earns a closer look as those pieces prove out.

AT&T (T) is the income-heavy telecom. It trades around $25 with a dividend yield near 4.5% and roughly 10–11 times forward earnings (as of May 29, 2026), and the wireless and fiber business has stabilized under a multi-year reset. The reason it is not in the main seven is deliberate: with Pfizer, Bristol Myers, and UPS already carrying the income load on this list, adding a high-debt, capital-intensive, slow-growth telecom would make the page too dividend-heavy. AT&T’s large net-debt load remains the watch item — recognizable and cheap, but with its own balance-sheet and growth questions.

The options angle

Cheap stocks are tricky for a reason that has nothing to do with price: the stock can look attractive while the timing is still wrong. That is where options can sometimes help — not by making a cheap stock safer, but by changing how much capital you commit and how the risk is shaped. Premium is never free money, and the stock thesis always has to come first.

If you actually want to own a beaten-down name right now, one approach is to sell an at-the-money or slightly in-the-money put. That collects more premium than selling a far out-of-the-money put, and it can be a more honest expression of the view — but only if you are genuinely willing to be assigned the shares. That phrase is the whole point. A put sale is still a bullish trade; if the stock keeps falling, you can still take real losses.

A second approach is a stock-replacement structure. Instead of tying up the full cost of the shares, an investor might use a deep-in-the-money call with roughly 60 days to expiration to get stock-like exposure with less capital committed. That can be useful when a name is still waiting to turn and you want exposure without parking as much cash in it.

Neither is a free lunch. A deep-in-the-money call is not the same as owning the stock: it carries expiration risk, liquidity and spread risk, and the possibility of losing the entire premium paid if the stock moves badly enough. These are positions professionals actively roll, adjust, or hedge — which is exactly why a beginner should understand the risk before using them, not after.

The Belanger point is simple. The stock thesis comes first. The option structure only matters if it improves the risk/reward or uses capital more efficiently — never as a way to force a weak idea. Cheap stocks are still cheap for a reason, and no structure fixes a broken thesis.

How to use this list

A watchlist is a starting point, not a shopping list. Five ways to use it well:

• This is research, not advice. Nothing here is a recommendation to buy a specific stock for your situation. Use it to decide what to study, then make your own call.
• Not every name is buyable today. Each is cheap for a reason. Understand what that reason is, and what would have to change before the discount closes.
• Cheap stocks need catalysts. A cheap stock with no catalyst can stay cheap for years. The names worth your time have something specific that could change how the market sees them.
• Size for the risk. A beaten-down blue chip and a deep-value China name do not belong at the same position size. Decide how much you can afford to be wrong on before you act.
• Do not treat low valuation as automatic upside. A low multiple on a shrinking business is a value trap, not a bargain. Price is not value.

For each name, the question is the same: what would prove the market wrong? If you can answer that in one sentence, you understand the setup. If you can’t, you are guessing.

For a broader, market-leadership-focused view, our best stocks to buy now watchlist looks at where real spending, earnings, and risk/reward line up across the market — a useful companion to this more value-and-bargain-focused page.

Frequently asked questions

What are cheap stocks? “Cheap” can mean a low share price, a low valuation (a low multiple of earnings, cash flow, or assets), a beaten-down price, or a genuinely undervalued business. Only the last two are automatically interesting — and a low share price by itself means almost nothing. A $5 stock can be expensive and a $250 stock can be a bargain. What matters is the price relative to what the business is worth.

Are cheap stocks good investments? Sometimes. A cheap stock is a good investment only when the market is mispricing the business — too pessimistic about a temporary problem, or missing a real catalyst. A stock that is cheap because the business is in lasting decline, drowning in debt, or constantly issuing new shares is not a bargain. Cheap does not mean good; cheap only matters when the market is mispricing the risk.

Is a low share price the same as a cheap valuation? No, and this is the single most common mistake. Share price tells you nothing on its own — it depends on how many shares exist. A company worth $1 billion can have a $5 stock or a $500 stock depending on its share count. Valuation (price relative to earnings, cash flow, or assets) is what tells you whether a stock is actually cheap.

What makes a cheap stock risky? The biggest risks are a deteriorating business, a weak balance sheet or heavy debt, ongoing dilution, no real catalyst, and a structural decline the market has correctly identified. The danger is buying a stock that is cheap for a reason — where the market has correctly priced a real problem — and mistaking it for a bargain.

How do you know if a cheap stock is undervalued? You compare the price to a reasonable estimate of what the business is worth, based on its earnings, cash flow, and assets, and you ask whether the reason it is cheap is something temporary the market is overreacting to, or something permanent the market has correctly identified. A specific catalyst, an improving trend, and a balance sheet that can survive the rough patch are the signs of genuine undervaluation rather than a value trap.

Should beginners buy cheap stocks? Beginners should be especially careful, because “cheap” stocks are where the most aggressive hype lives — particularly low-priced names on exciting themes. The lower-priced and more speculative a stock, the more research and the smaller the position it deserves, not the reverse. Starting with the framework on this page — cheap vs. broken — matters more than starting with any particular ticker.

Are cheap stocks better than expensive stocks? Not inherently. A “cheap” stock can be a value trap and an “expensive” stock can be a bargain if its growth justifies the price. What matters is the gap between price and value, not the headline multiple or the share price. Some of the best investments are quality businesses bought at a fair price, not broken businesses bought at a low one.

What is the difference between a cheap stock and a broken one? A cheap stock is one the market is too pessimistic about — the business still has real revenue, real cash flow, and a path to recovery, and the low price is mostly about sentiment. A broken stock is one where the business is genuinely deteriorating: a melting franchise, a balance sheet that can’t fund the turnaround, or a structural decline. Both look identical on a screener. The difference is always in the business, never in the price.

Can options be used on cheap stocks? They can, but with extra caution. Options on cheap or volatile stocks can magnify a mistake, and on thinly traded names the options themselves are often illiquid and expensive to trade. We only consider an option structure when it genuinely improves the risk/reward of an idea we already like — never as a way to pile extra risk onto a weak thesis.

Get the free Belanger Trading watchlist

Markets move fast. Belanger Trading tracks stock ideas, market warnings, and research for investors and traders — including the beaten-down and out-of-favor names worth a closer look, and the ones that only look like bargains. Get the free watchlist and see what we are watching, and why. Get the free Belanger Trading watchlist → No cost, unsubscribe anytime.

Last updated: May 30, 2026 — Belanger Trading updates this page as valuations, earnings, and risk/reward change.

Sources

• Nike (NKE) price ~$46, ~$68B market cap, ~3.5% yield, ~28x forward / ~30x trailing earnings — stockanalysis.com, May 29, 2026; fiscal Q3 2026 results (revenue ~$11.3B, net income -35% to $520M, Greater China -7%, ~20% China decline guide, North America +3% / footwear +6%, Elliott Hill “Win Now” turnaround) — CNBC, March 31, 2026; gross margin ~40.2% and tariff pressure, seventh straight China decline — WWD, 2026
• PayPal (PYPL) price ~$45 and ~8x earnings — stockanalysis.com, May 29, 2026; Q1 2026 results (revenue $8.35B +7%, EPS $1.34, TPV $464B, branded checkout +2%, Venmo +14%, $1.5B buyback / ~34M shares) — StockTitan / PayPal Q1 2026 8-K; board acknowledgment that branded checkout “fell short of expectations” and reorganization — PayPal DEFA14A, SEC
• UPS (UPS) price ~$107, ~$90.7B market cap, ~14x forward / ~17x trailing earnings, ~6.1% yield — stockanalysis.com, May 29, 2026; Q1 2026 results (revenue ~$21.2B, adjusted operating margin 6.2%, U.S. domestic operating profit $515M from $979M, revenue per piece +6.5%, peak margins 9–12% / recovery to 2028+, Amazon glidedown, FY2026 guide ~$89.7B revenue / ~9.6% adjusted operating margin) — Yahoo Finance, April 2026
• Target (TGT) price ~$127, ~$57.7B market cap, ~15x forward / ~17x trailing earnings, ~3.6% yield — stockanalysis.com, May 29, 2026; FY2025 results (net sales -1.7%, operating income -8.1%, Q4 comps -2.5%), Q1 2026 results (comps +5.6%, traffic +4.4%, gross margin +80 bps), >$2B incremental 2026 investment — Target Q1 2026 8-K, SEC
• Alibaba (BABA) ADS price ~$124, ~$284B market cap, ~18–19x earnings — stockanalysis.com, May 29, 2026; fiscal 2026 results (total revenue ~$148.4B +3% / +11% like-for-like, Cloud Intelligence Group +34% FY, AI triple-digit growth 11th straight quarter, $1.05/ADS ~$2.5B dividend) — Alibaba FY2026 results, May 12, 2026; buyback ($11.9B repurchased FY2025, ~$20.1B authorization remaining as of March 31, 2025, program effective through March 2027) — Alibaba share repurchase update
• Pfizer (PFE) price ~$26, ~9x forward earnings, ~6.6% yield — stockanalysis.com, May 29, 2026; patent cliff (Eliquis/Xeljanz 2026, Ibrance/Xtandi 2027) — TS2, 2026; ~99% payout ratio — The Motley Fool, January 3, 2026; Metsera obesity bet and 2026 Phase 3 data — AInvest, 2026; full-year 2026 guidance ($59.5–$62.5B revenue, $2.80–$3.00 EPS) and $2.4B Q1 2026 dividends — Pfizer Q1 2026 8-K, SEC
• Bristol Myers Squibb (BMY) price ~$57, ~9x forward earnings, ~4.4% yield, 17 consecutive years of dividend increases, FY2025 revenue ~$48.2B and 2026 guide ~$46–47.5B — InvestSnips, 2026 and stockanalysis.com, May 29, 2026; Eliquis/Opdivo ~2028 exclusivity loss and Revlimid generic erosion — The Motley Fool, May 24, 2026; 2026 pivotal readouts (Cobenfy, Milvexian, immunology, oncology) through 2028 — AInvest, 2026
• Kraft Heinz (KHC) price ~$24, ~6.5% yield, ~12x forward earnings — stockanalysis.com, May 29, 2026; split announced then paused in early 2026 under new CEO — The Detroit News, February 11, 2026
• Disney (DIS) price ~$102, ~14x forward earnings — stockanalysis.com, May 29, 2026; streaming profitability and record parks operating income — IndexBox, 2026
• AT&T (T) price ~$25, ~4.5% yield, ~10–11x forward earnings — stockanalysis.com, May 29, 2026; large net-debt load — WallStreetZen, 2026